Adverum Halts Phase II Gene Therapy Trial After Patient’s Vision Loss

29 Apr 2021

Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.

Adverum's significant adverse event is the latest setback in gene therapy development

The timing of a planned Phase III of Adverum Biotechnologies, Inc.’s gene therapy ADVM-022 in wet age-related macular edema (AMD) is in doubt after the company revealed on 28 April that it halted a Phase II study of ADVM-022 in diabetic macular edema (DME) following one patient losing vision in one eye.

The AMD trial was slated to begin

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.